Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia.
J Oncol Pharm Pract
; 25(8): 2035-2037, 2019 Dec.
Article
en En
| MEDLINE
| ID: mdl-30537918
ABSTRACT
We describe a case of dose-related periorbital edema in a patient with FLT3-mutated acute myeloid leukemia taking sorafenib and voriconazole that resolved following sorafenib dose reduction. We hypothesize that the mechanism of this adverse event may be related to the inhibition of platelet-derived growth factor receptor (PDGFR) by sorafenib. Clinicians should be aware of this possible dose-related adverse event and the potential role of sorafenib dose reduction when on concurrent voriconazole.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Leucemia Mieloide Aguda
/
Edema
/
Sorafenib
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Año:
2019
Tipo del documento:
Article